Press releaseGlobe Newswire
CytomX Therapeutics
CTMX · NASDAQ
$2.51+$0.17 (+7.26%)TodayMarket closed ·
Prev close $2.34
Latest news
- Press releaseGlobe Newswire
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
- Press releasePRNewswire
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
- News
CytomX Expands Collaboration And Licensing Agreement With Regeneron To Create Conditionally-Activated Bispecific Cancer Therapies Utilizing CytomX's Probody Therapeutic Platform And Regeneron's Veloci-Bi Bispecific Antibody Development Platform
- Press releaseGlobe Newswire
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- Press releaseGlobe Newswire
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
- News
CytomX Therapeutics Q1 EPS $(0.10) Beats $(0.20) Estimate, Sales $10.258M Beat $4.713M Estimate
- Press releaseGlobe Newswire
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsVandana Singh
Why Is CytomX Therapeutics Stock Falling On Wednesday?
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsAvi Kapoor
Crude Oil Down 4%; Dollar Tree Earnings Top Views
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
Market-Moving News for March 16th
- News
Earnings Scheduled For March 16, 2026
- News
CytomX Therapeutics Q4 EPS $(0.22) Misses $(0.09) Estimate, Sales $663.000K Miss $7.900M Estimate
- Press releaseGlobe Newswire
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
- NewsAvi Kapoor
CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
- News
Where CytomX Therapeutics Stands With Analysts
- NewsAvi Kapoor
Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- News
Earnings Scheduled For November 6, 2025
- News
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings)
- Press releasePRNewswire
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
- News
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsVandana Singh
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report
- News
Exploring CytomX Therapeutics's Earnings Expectations
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAvi Kapoor
Why Gap Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.